In the late 1980s, concern over holes in the ozone layer caused by chlorofluorocarbon (CFC) propellants triggered a concerted effort to transition to alternatives. Hydrofluoroalkane (HFA) propellants were brought in to replace CFCs across many sectors, including in consumer aerosols, refrigerants, and pressurised metered-dose inhalers (pMDIs).
Today, we are in the midst of another significant shift – this time not to protect the ozone layer, but to reduce greenhouse gas emissions caused by HFA propellants, which contribute to global warming.
Nick Atkinson, Head of Project Management, Drug Product Development, and Paul Sullivan, Managing Director at DH Industries sat down with PMPS as part of the Inhalation Technology Supplement to discuss how continued industry collaboration will be the key to enabling further progress and unlocking a greener future for pharma.
